Uropatógenos multirresistentes y con resistencia extendida a los antimicrobianos aislados en pacientes adultos de la comunidad de Barinas, Venezuela.
Multidrug-resistant and extensively antimicrobial-resistant uropathogens isolated from adult patients in Barinas, Venezuela.
Abstract
This study aimed to determine the frequency of multidrug-resistant (MDR) and extensively drug-resistant (XDR) uropathogens isolated from adult patients in Barinas City, Venezuela, in 2022. Of 1019 urine cultures from patients who attended the Barinas Clinical Microbiological Laboratory, 337 (33.07%) were selected according to inclusion criteria. The microbiological processing of urine was carried out through conventional methods. Antimicrobial susceptibility tests and extended-spectrum beta-lactamase determination were performed using standardized phenotypic methods. The classification of MDR and XDR strains was conducted according to international criteria. Data were processed through descriptive statistics and frequency analysis. Of 337 urine cultures analyzed, 70.92% corresponded to female patients, and the age groups between 31 and 60 years were the most frequent. Of the uropathogens identified, 93.17% were represented by Enterobacterales, where Escherichia coli stood out with 87.54%, followed by Pseudomonas aeruginosa (2.67%) and Enterococcus faecalis (1.48%). Of the E. coli strains, 87.12% presented resistance to at least one antibiotic, with 46.78% MDR and 5.42% XDR. In general, more than half of the uropathogens identified were distributed either as MDR or XDR phenotypes. The results show the need to develop local research to improve empirical and targeted therapies in urinary tract infections, in addition to awareness actions for the rational use of antibiotics and epidemiological surveillance of multiresistant strains circulating in the region.
Downloads
References
Klein RD, Hultgrena SJ. Urinary tract infections: microbial pathogenesis, host-pathogen interactions and new treatment strategies. Nat Rev Microbiol 2020; 18(4): 211–226. https://doi.org/10.1038/s41579-020-0324-0.
Guzmán M, Salazar E, Cordero V, Castro A, Villanueva A, Rodulfo H, De Donato M. Multidrug resistance and risk factors associated with community acquired urinary tract infections caused by Escherichia coli in Venezuela. Biomédica 2019; 39(Supl.1):96-106. https://doi.org/10.7705/biomedica.v39i2.4030
Yábar MN, Curi-Pesantes B, Torres CA, Calderón-Anyosa R, Riveros M, Ochoa TJ. Multirresistencia y factores asociados a la presencia de betalactamasas de espectro extendido en cepas de Escherichia coli provenientes de urocultivos. Rev Peru Med Exp Salud Pública 2017; 34(4):660-665. https://doi.org/10.17843/rp-mesp.2017.344.2922
Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. Multidrugresistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268–281.
León-Buitimea A, Morones-Ramírez JR, Yang JH. Peña-Miller R. Editorial: Facing the upcoming of multidrug-resistant and extensively drug-resistant bacteria: novel antimicrobial therapies (NATs). Front Bioeng Biotechnol 2021; 9:636278. https://doi.org/10.3389/fbioe.2021.636278.
World Health Organization. Antimicrobial resistance: global report on surveillance 2014. WHO; 2014. Geneva.
Millán Y, Hernández E, Millán B, Araque M. Distribución de grupos filogenéticos y factores de virulencia en cepas de Escherichia coli uropatógena productora de beta-lactamasa CTX-M-15 aisladas de pacientes de la comunidad en Mérida, Venezuela. Rev Argent Microbiol 2014; 46(3):175-181.
Hernández E, Araque M, Millán Y, Millán B, Vielma S. Prevalencia de β-lactamasa CTX-M-15 en grupos filogenéticos de Escherichia coli uropatógena aisladas en pacientes de la comunidad de Mérida, Venezuela. Invest Clín 2014; 55(1): 32-43.
Karen C. Carroll; Michael A. Pfaller; Marie Louise Landry; Robin Patel; Alexander J. McAdam; Sandra S. Richter; D. W. Warnock. Eds. Manual of Clinical Microbiology (ASM Books) 12th Ed. 2019. Washington (DC).
Clinical and Laboratory Standards Institute. Performance Standards for Anti- microbial Susceptibility Testing; 32th. Informational Supplement. CLSI Document M100-S27. Clinical and Laboratory Standards Institute, Wayne, PA.USA. 2022.
Marcos-Carbajal P, Galarza-Pérez M, Huancahuire-Vega S, Otiniano-Trujillo S, Soto-Pastrana J. Comparación de los perfiles de resistencia antimicrobiana de Escherichia coli uropatógena e incidencia de la producción de betalactamasas de espectro extendido en tres establecimientos privados de salud de Perú. Biomédica 2020; 40(Supl.1): 139-147. https://doi.org/10.7705/biomedica.4772.
Quijada-Martínez P, Flores-Carrero A, Labrador I, Araque M. Estudio clínico y microbiológico de las infecciones urinarias asociadas a catéter en los servicios de medicina interna de un hospital universitario venezolano. Rev Peru Med Exp Salud Pública 2017; 34(1):52-61.
Quijada-Martínez P, Flores-Carrero A, Labrador I, Millán Y, Araque M. Molecular characterization of multidrug-resistant Gram-negative bacilli producing catheter–associated urinary tract infections in internal medicine services of a Venezuelan University Hospital. Austin J Infect Dis 2017; 4(1): id1030.
Millán Y, Araque M. Ramírez A. Distribución de grupos filogenéticos, factores de virulencia y susceptibilidad antimicrobiana en cepas de Escherichia coli uropatógena. Rev Chilena Infect. 2020; 37(2):117-23.
Anger, JT, Bixler BR, Holmes, RS, Lee, UJ, Santiago-Lastra, Y, Selph SS. Updates to recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU Guideline. J Urology 2022; 208: 536-54. https://doi.org/10.1097/JU.00000000000 02860.
